PARP2 deficiency affects invariant-NKT-cell maturation and protects mice from concanavalin A-induced liver injury

Aveline Filliol1,2,3, Claire Piquet-Pellorce1,2,3, Sarah Dion1,2,3

  • 1Institut National de la Santé et de la Recherche Médicale, Institut de Recherche Santé Environnement et Travail, Rennes, France.

Insights

Genetic inactivation of Parp2 protects mice from concanavalin A-induced hepatitis by reducing invariant natural killer T cells. This finding highlights Parp2

Area of Science:

  • Immunology
  • Hepatology
  • Molecular Biology

Background:

  • Liver diseases are triggered by persistent inflammation and hepatocyte death.
  • Poly(ADP-ribose) polymerase (PARP) proteins are implicated in cell death and inflammation.
  • Chemical inhibition of PARP activity shows protective effects against liver injury.

Purpose of the Study:

  • To investigate the role of PARP proteins in liver immunity and inflammation.
  • To analyze immune cell populations in Parp2-deficient mice during ConA-induced hepatitis.
  • To determine if Parp2 deficiency impacts T-lymphocyte maturation and iNKT cell populations.

Main Methods:

  • Analysis of immune cell populations in liver and lymphoid organs (spleen, thymus, bone marrow) of Parp2-deficient mice.
  • Assessment of ConA-induced hepatitis in Parp2 knockout mice.
  • Evaluation of cytokine expression and leukocyte recruitment.

Main Results:

  • Genetic inactivation of Parp2, but not Parp1, protected mice from ConA hepatitis.
  • Cellularity was reduced in the thymus of Parp2-deficient mice.
  • Invariant natural killer T (iNKT) lymphocytes in spleen and liver, and T and NKT lymphocytes in the thymus were reduced in Parp2 knockout mice.

Conclusions:

  • Parp2 deficiency leads to a defect in T-lymphocyte maturation.
  • Systemic reduction of iNKT cells in Parp2 knockout mice protects against ConA-mediated liver damage.
  • Targeting Parp2 may offer a therapeutic strategy for liver diseases involving inflammation and cell death.